Analyst initiations: GSK, LVLT, SVNT, FREE and SINA
Posted Apr 1st 2008 11:40AM by Eric Buscemi
Filed under: Analyst Reports, Analyst Initiations, Level 3 Communications (LVLT), Savient Pharmaceuticals (SVNT)
.gif)
MOST NOTEWORTHY: GlaxoSmithKline, FreeSeas and SINA Corp were today's noteworthy initiations:
- ING believes GlaxoSmithKline (NYSE: GSK) should benefit from the appointment of Andrew Witty as CEO and see limited downside risks. The firm initiated shares with a Buy rating.
- FreeSeas (NASDAQ: FREE) was started at Oppenheimer with an Outperform rating and $8 target, as they view FREE as an early stage growth company in the smaller dry-bulk vessel segment and finds the valuation attractive at current levels.
- Kaufman Bros. initiated SINA Corp (NASDAQ: SINA) with a Buy rating and $4.50 target, and believes China represents a compelling long-term growth opportunity.
OTHER INITIATIONS:
- Level 3 Comm (NASDAQ: LVLT) was initiated with a Underperform rating at Wachovia.
- Jefferies assumed Savient Pharma (NASDAQ: SVNT) with a Buy rating and $30 target.
- Lehman initiated Brown & Brown (NYSE: BRO) with an Underweight rating.
Tags: free, freeseas, glaxosmithkline, gsk, level 3, level three, Level3, LevelThree, lvlt, savient, sina, svnt
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
